trending Market Intelligence /marketintelligence/en/news-insights/trending/aykj91-JXKgbFYrMOUjf2Q2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us
In This List

Sandu Pharmaceuticals fiscal Q2 profit falls YOY


ESG hits the mainstream for European private equity sponsors


What’s the Bottom Line: Credit Impact of COVID-19 on US Municipals


Banking Essentials Newsletter - February Edition, Part 2


Episode 3: Transformation of Customer Experience in 2020

Sandu Pharmaceuticals fiscal Q2 profit falls YOY

Sandu Pharmaceuticals Ltd. said its normalized net income for the fiscal second quarter ended Sept. 30 was 4 Indian paise per share, a decrease of 80.3% from 19 paise per share in the year-earlier period.

Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was 266,250 rupees, a decline of 80.2% from 1.3 million rupees in the year-earlier period.

The normalized profit margin dropped to 0.3% from 1.4% in the year-earlier period.

Total revenue increased 7.2% year over year to 104.6 million rupees from 97.6 million rupees, and total operating expenses climbed 9.1% from the prior-year period to 100.2 million rupees from 91.9 million rupees.

Reported net income decreased 93.2% from the prior-year period to 100,000 rupees, or 1 paise per share, from 1.5 million rupees, or 21 paise per share.

As of Nov. 13, US$1 was equivalent to 66.19 Indian rupees.